Table 3.
Univariate and multivariate analysis of Overall Survival (OS).
| Factors | N | Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|---|
| Median survival (months) | p | B | HR (95% CI) | p | ||
| Age (≤52/>52, years) | 42/42 | 42/18 | 0.041* | NS | ||
| Age of primary tumor (≤47/>47, years) | 38/46 | 33/36 | 0.447 | NI | ||
| Postmenopausal (no/yes) | 48/34 | 53/19 | 0.035* | NS | ||
| Primary tumor grade (low/high) | 28/51 | 29/33 | 0.989 | NI | ||
| Lymph node (negative/positive) | 24/55 | 37/33 | 0.701 | NI | ||
| Visceral metastasis (no/yes) | 65/14 | 37/8 | <0.001* | 0.868 | 2.383(1.032,5.501) | 0.042* |
| Pre-op chemotherapy (no/yes) | 27/57 | 39/33 | 0.757 | NI | ||
| Pre-op radiotherapy (no/yes) | 54/30 | 37/22 | 0.672 | NI | ||
| Pre-op endocrine/targeted therapy (no/yes) | 63/21(18/3) | 33/53 | 0.517 | NI | ||
| Cervical tumor (no/yes) | 66/18 | 36/33 | 0.945 | NI | ||
| Time of symptom (≤4/>4, weeks) | 57/27 | 36/29 | 0.714 | NI | ||
| Spine metastasis time (≤44/>44, months) | 37/39 | 37/18 | 0.116 | NI | ||
| Multiple metastases (no/yes) | 28/56 | 78/18 | 0.006* | 0.932 | 2.538(1.066,6.048) | 0.035* |
| ECOG Score (1,2/3–5) | 36/48 | 46/17 | <0.001* | NS | ||
| Pre-op Frankel score (A–C/D, E) | 39/45 | 16/39 | 0.002* | NS | ||
| Surgical excision or PVP (PVP/surgery) | 7/77 | 13/36 | 0.225 | NI | ||
| Blood loss (≤1500/>1500, ml) | 46/31 | 33/46 | 0.197 | NI | ||
| Post-op chemotherapy (no/yes) | 36/48 | 22/46 | 0.013* | −1.164 | 0.312(0.144,0.675) | 0.003* |
| Post-op radiotherapy (no/yes) | 63/21 | 29/46 | 0.200 | NI | ||
| Post-op endocrine/targeted therapy (no/yes) | 60/24(18/7) | 25/53 | 0.099* | NS | ||
| Bisphosphonate therapy (no/yes) | 25/59 | 16/46 | 0.001* | NS | ||